Amylin Pharmaceuticals

Amylin Pharmaceuticals, Inc.

Company type	Subsidiary
Traded as	Nasdaq: AMLN
Industry	Biotechnology
Founded	1987; 38 years ago (1987)
Defunct	2014 (2014)
Fate	Acquired by Bristol-Myers Squibb and AstraZeneca
Headquarters	San Diego, California, United States
Key people	Daniel M. Bradbury[1]
Products	Symlin (pramlintide) Byetta (exenatide) Bydureon (exenatide long-acting release)
Revenue	US$651 million (2011)[2]
Net income	US$−543 million (2011)[2]
Total assets	US$1.87 billion (2011)[2]
Total equity	US$−139 million (2011)[2]
Number of employees	1,300 (2011)[2]
Subsidiaries	Amylin Ohio LLC

Amylin Pharmaceuticals, Inc. is a biopharmaceutical founded in 1987 that was based in San Diego, California. The company was engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. Amylin produced three drugs: Symlin (pramlintide acetate), Byetta (exenatide) and Bydureon (exenatide extended release).